The pharmaceutical marketing company Medvi, hailed by the New York Times as a groundbreaking venture poised to surpass one billion dollars in revenue, has been embroiled in controversy following its recent profile. The article, which lauded Medvi’s innovative use of AI for business growth, sparked immediate online backlash over the ethical implications of the company’s practices. Medvi operates as a marketing wrapper for telehealth companies that prescribe and fulfill orders for GLP-1 agonists and other compounded drugs, using deceptive tactics to mislead consumers. The company has been accused of fabricating before-and-after client photos with AI, falsely claiming media coverage from mainstream outlets, and utilizing the likeness of medical practitioners without their consent. These allegations were largely ignored in the NYT’s profile, which downplayed or omitted these ethical red flags.
